Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab combined with GEMOX for relapsed/refractory extranodal NK/T-cell lymphoma after Peg-ASP regimen failure
ChiCTR1900022826Phase 2Recruiting
- Sponsor
- Union Hospital
- Start
- May 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, gemcitabine and oxaliplatin in extranodal natural killer/T-cell lymphoma (ENKTL), sponsored by Union Hospital. Primary endpoints: Complete response, Partial response and 1 more. Started May 2019; status: recruiting.
02
Drugs
sintilimabgemcitabineoxaliplatin
03
Conditions
extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on ChiCTR1900022826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022826.